Inovio Posts $49.2M Q3 Loss as First Commercial Launch of VOCERYQ Takes Shape
INO has more than doubled off its 52-week low of $0.563.
Summary
Inovio reported a Q3 net loss of $49.2 million, or $0.50 per share, but $26.9 million of that is a non-cash warrant remeasurement tied to share price, not operations. Operating expenses actually fell to $19.8 million from $21.2 million a year ago, with R&D down and SG&A up on launch preparation. Cash stood at $48.4 million at quarter-end; adding the $80.5 million November offering and $10.9 million in warrant proceeds, management now guides runway into late Q4 2027, past the VOCERYQ launch. The commercial timeline is the real story: VOCERYQ should be orderable roughly 60 days from the October 30 approval, with full field deployment in Q1 2027, and Syneos Health is handling field team recruitment. Watch the confirmatory study protocol submission to FDA by end of 2026 and the European conditional marketing authorization filing before year-end.
At the time of this announcement, INO was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.